Similar articles

• An approach to using recombinant erythropoietin for neuroprotection in very preterm infants.

  Fauchère JC, Dame C, Vonthein R, Koller B, Arri S, Wolf M, Bucher HU. Fauchère JC, et al. Pediatrics. 2008 Aug;122(2):375-82. doi: 10.1542/peds.2007-2591. Pediatrics. 2008. PMID: 18676556 Clinical Trial.
• [Influence of hemoglobin level and dose of administered recombinant human beta erythropoietin on survival of hemodialysis patients].

  Knezević V, Milosević A, Vodopivec S, Bozić D, Budosan I, Majić M. Knezević V, et al. Vojnosanit Pregl. 2011 Sep;68(9):749-55. doi: 10.2298/vsp1109749k. Vojnosanit Pregl. 2011. PMID: 22046879 Serbian.
• Use of human recombinant erythropoietin for the treatment of nonregenerative anemia in a rough-toothed dolphin (Steno bredanensis).

  Manire CA, Rhinehart HL. Manire CA, et al. J Zoo Wildl Med. 2000 Jun;31(2):157-63. doi: 10.1638/1042-7260(2000)031[0157:UOHREF]2.0.CO;2. J Zoo Wildl Med. 2000. PMID: 10982125
• Human recombinant erythropoietin in the prevention and treatment of anemia of prematurity.

  Ohls RK. Ohls RK. Paediatr Drugs. 2002;4(2):111-21. doi: 10.2165/00128072-200204020-00004. Paediatr Drugs. 2002. PMID: 11888358 Review.
• Erythropoietin use and abuse: When physiology and pharmacology collide.

  Spivak JL. Spivak JL. Adv Exp Med Biol. 2001;502:207-24. Adv Exp Med Biol. 2001. PMID: 11950139 Review.